Advertisement
Skip to Content

Gilead Sciences Inc GILD Stock Quote

| Rating as of

NASDAQ: GILD

Last close prices updated as of Feb 06, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 84.5
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 84.50  –  87.18
  • Year Range 57.17  –  89.74
  • Market Cap 107.6909 Bil
  • Volume / Avg 7.6 Mil /  7.3 Mil
  • Price / Sales 3.91
  • Price / Book 4.97
  • Forward Div Yield 3.55%
  • Trailing Div Yield 3.38%

Morningstar‘s Stock Analysis GILD

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Gilead’s Growth Starting to Look More Sustainable on Several Fronts; We're Raising Our FVE to $97

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

While Gilead’s 2022 bottom-line results were in line with our estimates, several drugs outperformed our sales expectations, and Gilead’s guidance and progress with its pipeline give us more confidence in the firm’s ability to sustain growth going forward (excluding volatility in demand for COVID-19 antivirals). We’re substantially raising our fair value estimate to $97 from $77, as we have boosted our long-term sales forecast for HIV drug Biktarvy after another quarter of outperformance, factored in long-term growth for cell therapy Yescarta as it works its way into earlier lines of treatment in more types of blood cancer, and also added Gilead’s oral COVID-19 antiviral, GS-5245, to our model, as it recently entered phase 3. We think that COVID-19 antiviral sales are likely to dip in 2023 but that the market could be more maintainable than we had anticipated. Despite faster growth in research and development expenses expected in 2023, we also now assume steadier spending as a percentage of sales in the long term. Partly countering these changes, we have slightly lowered our sales estimates for cancer drug Trodelvy. Despite Trodelvy's strong growth in triple negative breast cancer and the approval in HR-positive/HER2-negative breast cancer, as we think the competitive landscape in this indication will be challenging, given strong data in the HER2-low population for AstraZeneca and Daiichi Sankyo’s Enhertu. Overall, we think Gilead’s infectious disease and oncology franchises support a wide moat, and we think shares look slightly undervalued.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GILD

Company Profile GILD

Business Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Contact
333 Lakeside Drive
Foster, CA, 94404
Industry Drug Manufacturers - General
Employees 14,400

Related Articles GILD

FAQs for Gilead Sciences Inc Stock

Yes. GILD has a forward dividend yield of 3.55%. See GILD’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

GILD’s market cap is 107.69 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

GILD’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

GILD’s price/sales is 3.91.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

GILD’s price/forward earnings is 12.58.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

GILD’s price/book is 4.97.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See GILD’s valuation ratios compared to the Market Index.

GILD’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare GILD’s historical performance against its industry peers and the overall market.